In May Novartis announced that it had acquired the gene therapy pioneer AveXis in a $8.7 billion deal, but according to the the Swiss drug giant CEO Vas Narasimhan, he wishes he could have bought the company much earlier.
Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: ‘It’s A Challenge We Have To Solve’
